Stock JAZZ JAZZ PHARMACEUTICALS PLC
Add to a list
To use this feature you must be a member
Log inSign up

News Jazz Pharmaceuticals plc

Equities

JAZZ

IE00B4Q5ZN47

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
105.3 USD -0.17% Intraday chart for Jazz Pharmaceuticals plc -0.74% -14.41%
May. 31 Jazz Pharmaceuticals plc Announces Catherine Sohn, Pharm.D. Will Not Stand for Re-Election to the Board CI
May. 30 Jazz Pharmaceuticals Showcases Pioneering Research in Sleep Medicine at SLEEP 2024 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Jazz Pharmaceuticals plc Announces Catherine Sohn, Pharm.D. Will Not Stand for Re-Election to the Board
CI
Jazz Pharmaceuticals plc - Zanidatamab Granted Priority Review for HER2-Positive Metastatic Biliary Tract Cancer
AQ
Jazz Pharmaceuticals Showcases Pioneering Research in Sleep Medicine at SLEEP 2024
PR
Jazz Pharmaceuticals Showcases Pioneering Research in Sleep Medicine at SLEEP 2024
CI
Jazz Pharmaceuticals to Participate in Upcoming June Investor Conferences
PR
Sector Update: Health Care Stocks Lean Lower Premarket Wednesday
MT
Jazz Pharmaceuticals Says US FDA Grants Zanidatamab Priority Review to Treat HER2-Positive Metastatic Biliary Tract Cancer
MT
Jazz Pharmaceuticals plc Announces the U.S. Food and Drug Administration Accepted and Granted Priority Review of the Biologics License Application for Zanidatamab
CI
Jazz Pharmaceuticals Announces Collaboration with Life Science Cares to Improve the Wellbeing of Under Resourced Communities through Employee Volunteerism
PR
Transcript : Jazz Pharmaceuticals plc Presents at Bank of America Health Care Conference 2024, May-15-2024 10:00 AM
US reclassification could drive fresh research funding into pot sector
RE
Jazz Pharmaceuticals Insider Sold Shares Worth $548,250, According to a Recent SEC Filing
MT
Jazz Pharmaceuticals : Corporate Overview
PU
UBS Adjusts Price Target on Jazz Pharmaceuticals to $117 From $121, Maintains Neutral Rating
MT
Jazz Pharmaceuticals : Announces First Quarter 2024 Financial Results
PU
Jazz Pharmaceuticals Q1 Adjusted Earnings Decline, Revenue Rises; Reaffirms 2024 Outlook
MT
(JAZZ) JAZZ PHARMACEUTICALS Forecasts Fiscal Year 2024 EPS Range $18.15 - $19.35
MT
Earnings Flash (JAZZ) JAZZ PHARMACEUTICALS Reports Q1 Revenue $902M, vs. Street Est of $954.3M
MT
Earnings Flash (JAZZ) JAZZ PHARMACEUTICALS Posts Q1 EPS $2.68, vs. Street Est of $4.18
MT
Transcript : Jazz Pharmaceuticals plc, Q1 2024 Earnings Call, May 01, 2024
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. JAZZ Stock
  4. News Jazz Pharmaceuticals plc